A team from the SWOG Cancer Research Network that analyzed data on more than 20,000 patients from more than 200 clinical trials reports found that compared to men, women have a higher risk of severe adverse events from targeted therapy and immunotherapy. Past research has also shown that women tend to have more adverse events from chemotherapy.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
